# A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Source: https://onco.cc/trials/nct03383458/  
OnCo record `nct03383458` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Nivolumab in hepatocellular carcinoma, run by Bristol-Myers Squibb, active and no longer recruiting.

## Summary

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation is a phase 3 interventional study registered as NCT03383458 by Bristol-Myers Squibb, with 545 participants enrolled, started 2018-04-18 and due to reach its primary completion in 2026-05-27. Interventions recorded: Nivolumab, Placebo. Conditions listed: Hepatocellular Carcinoma, Liver Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03383458
- Phase: 3
- Setting: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
- Sponsor: Bristol-Myers Squibb
- Enrolled: 545

## Sources

- ClinicalTrials.gov NCT03383458: https://clinicaltrials.gov/study/NCT03383458

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct03383458.json